Skip to main content

Rabbit Polyclonal TRNT1 antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human, Mouse, Rat samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human TRNT1 aa 300-400.

Be the first to review this product! Submit a review

Images

Immunocytochemistry/ Immunofluorescence - Anti-TRNT1 antibody (AB224536), expandable thumbnail
  • Western blot - Anti-TRNT1 antibody (AB224536), expandable thumbnail
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRNT1 antibody (AB224536), expandable thumbnail
  • Western blot - Anti-TRNT1 antibody (AB224536), expandable thumbnail

Publications

Key facts

Isotype
IgG
Host species
Rabbit
Storage buffer

pH: 7.2
Preservative: 0.02% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine)

Form
Liquid
Clonality
Polyclonal

Immunogen

  • Recombinant Fragment Protein within Human TRNT1 aa 300-400. The exact immunogen used to generate this antibody is proprietary information. Database link Q96Q11

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
IHC-PWBICC/IF
Human
Tested
Tested
Tested
Mouse
Expected
Tested
Expected
Rat
Expected
Tested
Expected

Tested
Tested

Species
Human
Dilution info
1/200.00000 - 1/500.00000
Notes

Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Expected
Expected

Species
Mouse, Rat
Dilution info
Use at an assay dependent concentration.
Notes

-

Tested
Tested

Species
Mouse
Dilution info
0.04000-0.40000 µg/mL
Notes

-

Species
Rat
Dilution info
0.04000-0.40000 µg/mL
Notes

-

Species
Human
Dilution info
0.04000-0.40000 µg/mL
Notes

-

Tested
Tested

Species
Human
Dilution info
0.25000-2.00000 µg/mL
Notes

Fixation/Permeabilization: PFA/Triton X-100.

Expected
Expected

Species
Mouse, Rat
Dilution info
Use at an assay dependent concentration.
Notes

-

Target data

Function

Nucleotidyltransferase that catalyzes the addition and repair of the essential 3'-terminal CCA sequence in tRNAs, which is necessary for the attachment of amino acids to the 3' terminus of tRNA molecules, using CTP and ATP as substrates (PubMed:11504732, PubMed:25193871, PubMed:25640237, PubMed:25652405, PubMed:29454993, PubMed:30959222, PubMed:31011209, PubMed:34023389). tRNA 3'-terminal CCA addition is required both for tRNA processing and repair (PubMed:22076379, PubMed:25640237). Promotes tRNA repair and recycling downstream of the ribosome-associated quality control (RQC) pathway by mediating addition of the tRNA 3'-terminal CCA following cleavage by ANKZF1 and repair by ELAC1 (PubMed:31011209). Also involved in tRNA surveillance by mediating tandem CCA addition to generate a CCACCA at the 3' terminus of unstable tRNAs and tRNA-like transcripts (PubMed:22076379, PubMed:25640237). While stable tRNAs receive only 3'-terminal CCA, unstable tRNAs beginning with GG are marked with CCACCA and rapidly degraded (PubMed:22076379, PubMed:25640237). The structural flexibility of RNA controls the choice between CCA versus CCACCA addition: following the first CCA addition cycle, nucleotide-binding to the active site triggers a clockwise screw motion, producing torque on the RNA (PubMed:25640237). This ejects stable RNAs, whereas unstable RNAs are refolded while bound to the enzyme and subjected to a second CCA catalytic cycle (PubMed:25640237). Isoform 2. Adds 2 C residues (CC-) to the 3' terminus of tRNA molecules instead of a complete CCA end as isoform 1 does (in vitro).

Alternative names

Recommended products

Rabbit Polyclonal TRNT1 antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human, Mouse, Rat samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human TRNT1 aa 300-400.

Key facts

Isotype
IgG
Form
Liquid
Clonality
Polyclonal
Immunogen
  • Recombinant Fragment Protein within Human TRNT1 aa 300-400. The exact immunogen used to generate this antibody is proprietary information. Database link Q96Q11
Purification technique
Affinity purification Immunogen
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

TRNT1 also known as tRNA nucleotidyl transferase 1 is a protein that attaches the CCA sequence to the 3' end of tRNA molecules. This addition is essential for transferring amino acids during protein synthesis. TRNT1 has a molecular mass of about 48 kDa. The protein is expressed in many tissues but is particularly abundant in metabolically active tissues like heart and liver where protein synthesis is high.

Biological function summary

The addition of the CCA tail is a necessary step at the end of tRNA maturation. Without this tRNA molecules cannot function in protein synthesis. TRNT1 does not work alone; it complements the function of other tRNA modifying enzymes adding the correct nucleotides to tRNA. TRNT1 frequently interacts with other molecules to ensure the processing is accurate and efficient.

Pathways

TRNA CCA addition by TRNT1 plays a role in RNA processing and protein synthesis pathways. These pathways are fundamental for cell function impacting how cells make proteins. TRNT1 interacts with other RNA-related proteins like tRNA synthetases which help link tRNA to specific amino acids. This interaction shows the connectedness of TRNT1 with proteins involved in translational machinery.

Associated diseases and disorders

Improper function of TRNT1 associates with sideroblastic anemia with B-cell immunodeficiency periodic fevers and developmental delay (SIFD). In this context inadequate TRNT1 activity leads to defective tRNA maturation contributing to disease symptoms. TRNT1’s malfunction can also relate to other proteins in these diseases such as mutant forms of certain mitochondrial proteins exacerbating clinical features.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

  • Immunocytochemistry/ Immunofluorescence - Anti-TRNT1 antibody (ab224536), expandable thumbnail

    Immunocytochemistry/ Immunofluorescence - Anti-TRNT1 antibody (ab224536)

    PFA-fixed, Triton X-100 permeabilized A431 (human epidermoid carcinoma cell line) cells stained for TRNT1 (green) using ab224536 at 4 μg/ml in ICC/IF.

  • Western blot - Anti-TRNT1 antibody (ab224536), expandable thumbnail

    Western blot - Anti-TRNT1 antibody (ab224536)

    All lanes: Western blot - Anti-TRNT1 antibody (ab224536) at 1/100 dilution

    All lanes: A549 (human lung carcinoma cell line) cell lysate

    Developed using the ECL technique.

    Predicted band size: 50 kDa

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRNT1 antibody (ab224536), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRNT1 antibody (ab224536)

    Paraffin-embedded human stomach tissue stained for TRNT1 using ab224536 at 1/200 dilution in immunohistochemical analysis.

  • Western blot - Anti-TRNT1 antibody (ab224536), expandable thumbnail

    Western blot - Anti-TRNT1 antibody (ab224536)

    All lanes: Western blot - Anti-TRNT1 antibody (ab224536) at 1/100 dilution

    Lane 1: NIH/3T3 (mouse embryonic fibroblast cell line) cell lysate

    Lane 2: NBT-II cell lysate

    Developed using the ECL technique.

    Predicted band size: 50 kDa

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com